ストックスクリーナーアプリを入手
5.50
1.20%
0.065
前日終値:
$5.435
開ける：
$5.4
24時間の取引高:
712.92K
Relative Volume:
0.55
時価総額：
$763.89M
収益：
$62.04M
当期純損益:
$-533.34M
株価収益率:
-1.4031
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
+4.17%
1か月 パフォーマンス:
-21.48%
6か月 パフォーマンス:
-28.76%
1年 パフォーマンス:
-33.33%
1日の値動き範囲:
$5.34
$5.525
1週間の範囲:
$5.23
$5.73
52週間の値動き範囲:
$4.95
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
VIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.50 | 763.89M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
5 Analysts Have This To Say About Vir Biotechnology - Benzinga
Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock - Investing.com
Vir Biotechnology CEO Sells Shares to Cover Tax Obligations - TradingView
Vir Biotechnology stock hits 52-week low at $6.07 By Investing.com - Investing.com Australia
Vir Biotechnology stock hits 52-week low at $6.07 - Investing.com
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution - simplywall.st
Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo
Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India
(VIR) Trading Advice - news.stocktradersdaily.com
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow
Hepatitis D Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
(VIR) Trading Signals - Stock Traders Daily
Morgan Stanley maintains $20 target on Vir Biotechnology stock By Investing.com - Investing.com Canada
Morgan Stanley maintains $20 target on Vir Biotechnology stock - Investing.com India
Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection - Marketscreener.com
Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial -March 13, 2025 at 08:30 am EDT - Marketscreener.com
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus
SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $35.67 - Defense World
Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN
Principal Financial Group Inc. Has $3.28 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund - Defense World
Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology's (VIR) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
What is HC Wainwright’s Forecast for VIR Q1 Earnings? - Defense World
(VIR) On The My Stocks Page - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for Vir Biotechnology (NASDAQ:VIR) - Defense World
Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating - TipRanks
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, Barclays Analyst Says - Defense World
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Canada Finance
7 Analysts Have This To Say About Vir Biotechnology - Benzinga
Decoding Vir Biotechnology Inc (VIR): A Strategic SWOT Insight - GuruFocus.com
Vir Biotechnology’s Transformative Year: Earnings Call Insights - TipRanks
Vir Biotechnology Becomes Oversold (VIR) - Nasdaq
Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock By Investing.com - Investing.com Canada
Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock - Investing.com India
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript - Insider Monkey
Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology - TipRanks
Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):